BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23122536)

  • 1. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.
    Yi M; Kuerer HM; Mittendorf EA; Hwang RF; Caudle AS; Bedrosian I; Meric-Bernstam F; Wagner JL; Hunt KK
    J Am Coll Surg; 2013 Jan; 216(1):105-13. PubMed ID: 23122536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.
    Weiss A; Mittendorf EA; DeSnyder SM; Hwang RF; Bea V; Bedrosian I; Hoffman K; Adrade B; Sahin AA; Kuerer HM; Hunt KK; Caudle AS
    Clin Breast Cancer; 2018 Aug; 18(4):276-281. PubMed ID: 29100726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection.
    Nayyar A; Strassle PD; Shen MR; Black JA; Gallagher KK; McGuire KP
    Am J Surg; 2018 Oct; 216(4):706-712. PubMed ID: 30060915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
    Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
    Giuliano AE; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Hunt KK; Morrow M; Ballman K
    Ann Surg; 2010 Sep; 252(3):426-32; discussion 432-3. PubMed ID: 20739842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
    Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
    Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology.
    Mattar D; Di Filippo A; Invento A; Radice D; Burcuta M; Bagnardi V; Magnoni F; Santomauro G; Corso G; Mazzarol G; Viale G; Sacchini V; Galimberti V; Veronesi P; Intra M
    Eur J Surg Oncol; 2021 Oct; 47(10):2499-2505. PubMed ID: 34172359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
    Lucci A; McCall LM; Beitsch PD; Whitworth PW; Reintgen DS; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Giuliano AE;
    J Clin Oncol; 2007 Aug; 25(24):3657-63. PubMed ID: 17485711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
    Shah-Khan M; Boughey JC
    Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
    Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
    Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Importance of Applying ACOSOG Z0011 Criteria in the Axillary Management of Invasive Lobular Carcinoma: A Multi-institutional Cohort Study.
    Roberts A; Nofech-Mozes S; Youngson B; McCready DR; Al-Assi M; Ramkumar S; Cil T
    Ann Surg Oncol; 2015 Oct; 22(10):3397-401. PubMed ID: 26215196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
    Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
    Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database.
    Wang J; Mittendorf EA; Sahin AA; Yi M; Caudle A; Hunt KK; Wu Y
    PLoS One; 2014; 9(2):e89778. PubMed ID: 24587029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
    Mamtani A; Zabor EC; Stempel M; Morrow M
    Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy.
    Dengel LT; Van Zee KJ; King TA; Stempel M; Cody HS; El-Tamer M; Gemignani ML; Sclafani LM; Sacchini VS; Heerdt AS; Plitas G; Junqueira M; Capko D; Patil S; Morrow M
    Ann Surg Oncol; 2014 Jan; 21(1):22-7. PubMed ID: 23975314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.